SynKIR-310 for Relapsed/Refractory B-NHL

Clinical trial NCT06544265 · RECRUITING

Trial details

NCT number: NCT06544265
Sponsor: Verismo Therapeutics
Status: RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

B Cell Lymphoma NHL, Adult Mantle Cell Lymphoma Relapsed Non-Hodgkin Lymphoma Refractory Non-Hodgkin Lymphoma Aggressive B-Cell Non-Hodgkin Lymphoma Indolent B-Cell Non-Hodgkin Lymphoma Follicular Lymphoma Marginal Zone Lymphoma DLBCL - Diffuse Large B Cell Lymphoma HGBL With MYC and BCL2 and/or BCL6 Rearrangements High-grade B-cell Lymphoma

Start date: 2024-11-01
Primary completion: 2028-09-01
Enrollment: 36

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.